News

The FDA has accepted a biologics license application for tisagenlecleucel and granted it priority review as a potential treatment for relapsed or refractory follicular lymphoma after 2 lines of therapy

Patients with advanced ovarian cancer who respond to platinum-based chemotherapy are eligible for olaparib monotherapy. Data from the SOLO1 trial found that the safety profile of the agent is manageable.

Guiseppe Curigliano, MD, discusses the rationale behind a subgroup HER2CLIMB study, which evaluated the efficacy and safety of tucatinib in combination with trastuzumab and capecitabine in pretreated HER2-positive breast cancer patients with and without brain metastases compared with placebo.

Frederick Howard, MD, a medical oncology fellow in the Department of Medicine at the University of Chicago, discussed the clinical benefits of the SimBioSys TumorScope model for the treatment of early breast cancer in an interview with Targeted Oncology.

Through a new a new collaborative partnership, Florida Cancer Specialists & Research Institute plans to build a proton therapy center in the Tampa Bay area of Florida.

A new Florida Cancer Specialists & Research Institute location has opened to providing the most advanced and personalized treatments and services for patients with all forms of cancers and blood disorders.

The trial is designed to evaluate eltanexor monotherapy in high-risk MDS. It is recruiting in 8 separate states.

In an interview with Targeted Oncology, study investigator David Dawe, MD, BASc, MSC, FRCPC, discussed the impact of age, comorbidities, and polypharmacy on cancer care in greater detail.

Topline results show that the addition of eryaspase to chemotherapy does not prolong survival in the general advanced pancreatic cancer population, but there may be benefit for those treated with irinotecan.

The phase CANOPY-1 study has missed its co primary end points, but signals observed in a non–small cell lung cancer subgroup warrant further investigation.

Significant survival improvement was achieved with durvalumab in combination with chemotherapy as treatment of patients with biliary tract cancer.

The American Oncology Network has earned accreditation for specialty pharmacy practice and for digital pharmacy practice.

Melphalan flufenamide is being removed from the US market after the OCEAN study failed to show an improvement in OS over pomalidomide and dexamethasone. The agent was granted approval for use in R/R MM in February.

With a fast track designation for platinum-resistant ovarian cancer, development of the agent in this disease state will be expedited to potentially fill an unmet medical need.

Adding the oral mutant isocitrate dehydrogenase-2 inhibitor enasidenib to azacitidine helps to extend ORR in patients with AML, compared to azacitidine monotherapy.

The treatment of platinum-resistant ovarian cancer is challenging, with limited therapeutic options. Antibody-drug conjugates as single agents or in combinations are showing promise for these patients.

Good activity was seen with acalabrutinib in combination with venetoclax and obinutuzumab in the front-line setting for select patients with chronic lymphocytic leukemia.

During a recent tweet chat with Sheena Mukkada, MD, MPH, an assistant member of the St. Jude Children’s Research Hospital, joined Targeted Oncology to discuss how the COVID-19 pandemic has impacted pediatric cancer care.

The extended use of aromatase inhibitor therapy beyond 5 years remains controversial. However, a new study found that extending letrozole use significantly improves disease-free survival in postmenopausal patients with breast cancer.

The assay is meant to determine patient eligibility for atezolizumab, which was granted FDA approval in PD-L1-positive lung cancer on October, 15. The assay was used in the IMpower010 study.

The primary end point of the phase 3 SOLSTICE study of trifluridine and tipiracil plus bevicizumab versus capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer was not met.

The ATLEP study explored the combination of lenvatinib and pembrolizumab in patients with ATC and poorly differentiated thyroid cancer.

Florida Cancer Specialists & Research Institute has received a three-year accreditation from the National Accreditation Program for Breast Centers.

A fast-track designation was granted to a universal cancer vaccine in combination with checkpoint inhibitors. The vaccine, UV1, can be used in combination with either pembrolizumab or ipilimumab.

Both the primary and key secondary end point of the phase 3 EMERALD study have been reached.

Michael Wang, MD, discusses the real-world efficacy of brexucabtagene autoleucel, the first chimeric antigen receptor T-cell therapy for the treatment of mantle cell lymphoma.

In an interview with Targeted Oncology, Evanthia Roussos Torres, MD, PhD, discussed the phase 1 investigation of the safety and efficacy of entinostat administered in combination with nivolumab and ipilimumab for the treatment of advanced HER2-negative breast cancer.

A trial is currently recruiting across the US to investigate the safety of a new anti-PD-1/CD3 antibody for the treatment of relapsed or refractory T-cell lymphoma. It aims to enroll 86 patients.

In a randomized study, geriatric assessment-driven intervention was effective in reducing chemotherapy-related toxicities in older patients with cancer.

The primary end point of the ROMAN trial was not reached after avasopasem was found to not significantly reduce the incidence of severe oral mucositis. A full analysis of the results is ongoing.